Cargando…

Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti‐transcriptional intermediary factor 1‐γ antibody‐positive dermatomyositis: A case report

Autoimmune diseases (ADs) are closely related to cancers; 30% of dermatomyositis (DM) cases are associated with malignancy. In lung cancer patients accompanied by DM, the most frequent cancer type is small cell lung cancer (SCLC). Anti‐transcriptional intermediary factor 1 γ (anti‐TIF1γ) antibody is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Yoonjoo, Park, Dongil, Choi, Song‐Yi, Chung, Chaeuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527166/ https://www.ncbi.nlm.nih.gov/pubmed/35982637 http://dx.doi.org/10.1111/1759-7714.14609

Ejemplares similares

Anti-transcription Intermediary Factor1γ-antibody-positive Dermatomyositis Complicated by Dysphagia
por: Kurushima, Shota, et al.
Publicado: (2017)

Small cell lung cancer and interstitial pneumonia associated with anti‐transcriptional intermediary factor‐1γ‐positive dermatomyositis
por: Kato, Toshio, et al.
Publicado: (2019)

Case Report: IgA Nephropathy in a Patient With Anti-Transcription Intermediary Factor-1γ Antibody-Positive Dermatomyositis
por: Zhang, Suo, et al.
Publicado: (2022)

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer
por: Sato, Yuki, et al.
Publicado: (2022)

SCLC, Paraneoplastic Dermatomyositis, Positive Transcription Intermediary Factor 1-γ, and Point Mutation in the Transcription Intermediary Factor 1-γ Coding Gene: A Case Report
por: Arnon, Johnathan, et al.
Publicado: (2021)

Anti-transcriptional intermediary factor-1γ antibody-positive dermatomyositis in a patient with triple-negative breast cancer treated with adjuvant capecitabine
por: Kessler, Alaina J., et al.
Publicado: (2023)

Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1γ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy
por: Aritomi, Takafumi, et al.
Publicado: (2018)

The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis
por: Oldroyd, Alexander, et al.
Publicado: (2019)

Comment on: The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis: Reply
por: Oldroyd, Alexander, et al.
Publicado: (2019)

Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature
por: Ono, Ryohei, et al.
Publicado: (2021)

Right middle lobe obstruction associated with synchronous endobronchial carcinoid and aspergillosis
por: Kim, Yoonjoo, et al.
Publicado: (2021)

Transthoracic Needle Biopsy: How to Maximize Diagnostic Accuracy and Minimize Complications
por: Chung, Chaeuk, et al.
Publicado: (2020)

Lung adenocarcinoma and anti‐transcriptional intermediary factor 1‐gamma positive dermatomyositis complicated with spontaneous oesophageal rupture
por: Saraya, Takeshi, et al.
Publicado: (2019)

The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer
por: Kang, Da Hyun, et al.
Publicado: (2022)

Autoantibodies to transcription intermediary factor (TIF)1β associated with dermatomyositis
por: Satoh, Minoru, et al.
Publicado: (2012)

My-Lupus: A case of anti-transcriptional intermediary factor 1-gamma antibody-positive dermatomyositis overlapping with discoid lupus erythematosus in an adult patient
por: Toker, Michelle, et al.
Publicado: (2023)

New Insights into the Clinical Implications of Yes-Associated Protein in Lung Cancer: Roles in Drug Resistance, Tumor Immunity, Autophagy, and Organoid Development
por: Yoo, Geon, et al.
Publicado: (2021)

The Tri-iodothyronine (T3) Level Is a Prognostic Factor for Patients With Advanced NSCLC: Receiving Immune Checkpoint Inhibitors and Is Associated With Liver Metastasis
por: Kim, Yoonjoo, et al.
Publicado: (2022)

Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy
por: Harada, Yumi, et al.
Publicado: (2022)

A Case of Dermatomyositis Along with Esophageal Cancer and Screening of Serum Transcriptional Intermediary Factor 1 Gamma Antibodies in Various Cancer Patients
por: Sumazaki, Makoto, et al.
Publicado: (2020)

Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis
por: Nakanishi, Yu, et al.
Publicado: (2020)

Marked Improvement of Anti-TIF1-γ Antibody-Positive Dermatomyositis After Chemoradiotherapy to Relevant Nasopharyngeal Cancer
por: Tomita, Natsuo, et al.
Publicado: (2021)

Case of Anti-Small Ubiquitin-Like Modifier Activating Enzyme Antibody-Positive Dermatomyositis with Sarcoidosis
por: Sakano, Kei, et al.
Publicado: (2023)

Analysis of human total antibody repertoires in TIF1γ autoantibody positive dermatomyositis
por: Megremis, Spyridon, et al.
Publicado: (2021)

Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers
por: Imai, Ryosuke, et al.
Publicado: (2021)

Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
por: Thomas, Rachel, et al.
Publicado: (2021)

A unique case of dermatomyositis associated with anti-TIF1γ antibody and chondrosarcoma
por: Dziwis, Jennifer, et al.
Publicado: (2019)

Scientific Validation and Clinical Application of Lung Cancer Organoids
por: Lee, Dahye, et al.
Publicado: (2021)

The Zebrafish moonshine Gene Encodes Transcriptional Intermediary Factor 1γ, an Essential Regulator of Hematopoiesis
por: Ransom, David G, et al.
Publicado: (2004)

Transcriptional Intermediary Factor 1γ binds to the Anaphase-Promoting Complex/Cyclosome and promotes mitosis
por: Sedgwick, Garry G., et al.
Publicado: (2012)

Clinical Features of Dermatomyositis/Polymyositis with Anti-MDA5 Antibody Positivity
por: Chen, Qiuhe, et al.
Publicado: (2022)

Artificial intelligence for antibody reading comprehension: AntiBERTa
por: Choi, Yoonjoo
Publicado: (2022)

Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors
por: Kang, Da Hyun, et al.
Publicado: (2021)

Hepatic stellate cell–specific knockout of transcriptional intermediary factor 1γ aggravates liver fibrosis
por: Lee, Eun Ju, et al.
Publicado: (2020)

Anti-MDA5 antibody-positive dermatomyositis presenting as unilateral eyelid edema
por: Chen, Lauren, et al.
Publicado: (2020)

Cosuppression of NF-κB and AICDA Overcomes Acquired EGFR-TKI Resistance in Non-Small Cell Lung Cancer
por: Yeo, Min-Kyung, et al.
Publicado: (2022)

Therapeutic Effects of Treating COVID-19 Vaccine-Induced Anti-TIF1-γ-Positive Dermatomyositis
por: Wu, Chih-Feng, et al.
Publicado: (2023)

Circulating VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis
por: Li, Xiaomeng, et al.
Publicado: (2022)

Editorial: Anti-MDA5-Positive Dermatomyositis
por: Gono, Takahisa, et al.
Publicado: (2022)

Myocardial involvement is not rare in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis/clinically amyopathic dermatomyositis: a retrospective study
por: Zhou, Shuang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u4vjtdssjm9m40183kr4iaf6vf